A Phase 2 Extension of Study GCS-100-CS-4003

Trial Profile

A Phase 2 Extension of Study GCS-100-CS-4003

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to withdrawn prior to enrolment.
    • 13 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top